Patients possessing the dominant genotype (GA + AA) of the IL17A-G197A gene polymorphism have a risk 3.91 times greater of developing at least a one-stage increase in liver fibrosis than individuals with the GG genotype (adjusted OR = 3.91, 95% CI: 1.33–12.34). The gene discussed is IL17A; the disease is Hepatic fibrosis.